Press release
Metastatic Renal Cell Carcinoma Clinical Pipeline | Over 40 Companies Driving the Future of Treatment
Metastatic Renal Cell Carcinoma Clinical Pipeline
DelveInsight's 'Metastatic Renal Cell Carcinoma Pipeline Insight 2025' report provides comprehensive global coverage of pipeline Metastatic Renal Cell Carcinoma therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Metastatic Renal Cell Carcinoma pipeline domain.
For emerging Metastatic Renal Cell Carcinoma drugs, the Metastatic Renal Cell Carcinoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Metastatic Renal Cell Carcinoma Pipeline Report
• DelveInsight's Metastatic Renal Cell Carcinoma Pipeline analysis depicts a robust space with 40+ active players working to develop 50+ pipeline drugs for Metastatic Renal Cell Carcinoma treatment.
• The leading Metastatic Renal Cell Carcinoma companies include AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics, Eli Lilly and Company, Xynomic Pharmaceuticals, AnewPharma, HUTCHMED, MedImmune, Incyte Corporation, NiKang Therapeutics, OncoC4, Inc., Nanobiotix, Aravive, Mirati Therapeutics Inc., BeiGene, Shanghai PerHum Therapeutics Co., Ltd., Akeso Biopharma, Novartis Pharmaceuticals, Vaccibody, SillaJen, Inc., Chongqing Precision Biotech Co., Ltd., Infinity Pharmaceuticals, Inc., SOTIO Biotech AG, Pfizer, Peloton Therapeutics, Inc., NeoTX Therapeutics Ltd., and others are evaluating their lead assets to improve the Metastatic Renal Cell Carcinoma treatment landscape.
• Key Metastatic Renal Cell Carcinoma pipeline therapies in various stages of development include Atezolizumab, Olaparib, TP-1454, and others.
• In March 2025, Oncorena announced that the FDA has approved its IND application for the Phase I/II Oncorella-1 study (NCT05287945, ONC001-CL-001), which will evaluate the safety, tolerability, and anti-tumor efficacy of orellanine in patients with metastatic clear-cell or papillary renal cell carcinoma.
• In February 2025, Telix Pharmaceuticals announced the FDA accepted the Biologics License Application for TLX250-CDx, a novel imaging agent for kidney cancer, granting it Priority Review. This brings Telix closer to potentially launching the first imaging agent to diagnose clear cell renal cell carcinoma accurately.
Request a sample and discover the recent breakthroughs happening in the Metastatic Renal Cell Carcinoma pipeline landscape @ https://www.delveinsight.com/report-store/metastatic-renal-cell-carcinoma-mrcc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Metastatic Renal Cell Carcinoma Overview
Renal cell carcinoma (RCC) is the most prevalent form of kidney cancer in adults, accounting for approximately 85% of kidney-originating tumors. The disease often remains undetected for much of its progression, with only 10% of patients exhibiting the classic triad of flank pain, hematuria, and a palpable flank mass.
Metastatic spread occurs in around 33% of RCC cases, posing significant challenges in clinical management due to the limited effectiveness of available treatments. RCC commonly metastasizes to the lungs, liver, bones, brain, and adrenal glands, though it has been reported to spread to nearly any part of the body. The metastatic process frequently involves multiple organ systems and may be present at diagnosis or emerge at some point after nephrectomy. Between 20% and 50% of patients eventually develop metastatic disease following nephrectomy, with a shorter interval between surgery and metastasis linked to a poorer prognosis.
The outlook for metastatic RCC remains poor, with a median survival of only 6 to 12 months and a 2-year survival rate of 10% to 20%.
Find out more about Metastatic Renal Cell Carcinoma medication @ https://www.delveinsight.com/report-store/metastatic-renal-cell-carcinoma-mrcc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Metastatic Renal Cell Carcinoma Treatment Analysis: Drug Profile
Olaparib: AstraZeneca
Olaparib is a potent and selective inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, specifically PARP1 and PARP2. As part of a novel class of anti-cancer therapies, PARP inhibitors exploit defects in DNA repair mechanisms in cancer cells with BRCA mutations, ultimately inducing cell death. Olaparib is approved for the treatment of various BRCA-associated cancers, including ovarian, breast, pancreatic, and prostate cancer. Initially approved by the FDA and EU in December 2014, the drug is currently undergoing Phase II clinical trials for the treatment of metastatic renal cell carcinoma.
Atezolizumab: Genentech
Atezolizumab is a humanized IgG antibody that targets PD-L1, blocking its interaction with PD-1 and B7-1. By preventing PD-L1 from binding to PD-1, it enhances anti-tumor immune responses without triggering antibody-dependent cellular cytotoxicity. This therapy is specifically indicated for patients whose tumors express PD-L1, those ineligible for platinum-based chemotherapy, or those whose tumors do not respond to platinum-based treatment. Atezolizumab received FDA approval on October 18, 2016, and is currently in Phase III clinical trials for the treatment of metastatic renal cell carcinoma.
Key Metastatic Renal Cell Carcinoma Therapies and Companies
• Olaparib: AstraZeneca
• TP-1454: Sumitomo Dainippon Pharma
• Atezolizumab: Genentech
Learn more about the novel and emerging Metastatic Renal Cell Carcinoma pipeline therapies @ https://www.delveinsight.com/report-store/metastatic-renal-cell-carcinoma-mrcc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Metastatic Renal Cell Carcinoma Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
By Molecule Type
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
Scope of the Metastatic Renal Cell Carcinoma Pipeline Report
• Coverage: Global
• Key Metastatic Renal Cell Carcinoma Companies: AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics, Eli Lilly and Company, Xynomic Pharmaceuticals, AnewPharma, HUTCHMED, MedImmune, Incyte Corporation, NiKang Therapeutics, OncoC4, Inc., Nanobiotix, Aravive, Mirati Therapeutics Inc., BeiGene, Shanghai PerHum Therapeutics Co., Ltd., Akeso Biopharma, Novartis Pharmaceuticals, Vaccibody, SillaJen, Inc., Chongqing Precision Biotech Co., Ltd., Infinity Pharmaceuticals, Inc., SOTIO Biotech AG, Pfizer, Peloton Therapeutics, Inc., NeoTX Therapeutics Ltd., and others.
• Key Metastatic Renal Cell Carcinoma Pipeline Therapies: Atezolizumab, Olaparib, TP-1454, and others.
Dive deep into rich insights for drugs used for Metastatic Renal Cell Carcinoma treatment; visit @ https://www.delveinsight.com/report-store/metastatic-renal-cell-carcinoma-mrcc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Metastatic Renal Cell Carcinoma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Metastatic Renal Cell Carcinoma Pipeline Therapeutics
6. Metastatic Renal Cell Carcinoma Pipeline: Late-Stage Products (Phase III)
7. Metastatic Renal Cell Carcinoma Pipeline: Late-Stage Products (Phase III)
8. Metastatic Renal Cell Carcinoma Pipeline: Mid-Stage Products (Phase II)
9. Metastatic Renal Cell Carcinoma Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Renal Cell Carcinoma Clinical Pipeline | Over 40 Companies Driving the Future of Treatment here
News-ID: 3927603 • Views: …
More Releases from DelveIinsight
Lou Gehrig's Disease Pipeline: 75+ Innovators Pioneering Breakthrough Therapies …
The Lou Gehrig's Disease market is rapidly advancing and is fueled by groundbreaking research and innovative therapies from companies such as Denali Therapeutics, AbbVie, Calico Life Sciences, and Clene Nanomedicine Biosciences. These industry pioneers are transforming treatment strategies and redefining the future of Lou Gehrig's Disease, bringing new hope to patients worldwide.
DelveInsight's "Lou Gehrig's Disease Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Lou…
Herpes Labialis Clinical Pipeline |6+ Companies Driving the Next Generation of T …
The Herpes Labialis market is rapidly advancing, fueled by groundbreaking research and innovative therapies from companies such as AiCuris, Heidelberg ImmunoTherapeutics, and Ecogene 21. These industry pioneers are transforming treatment strategies and redefining the future of Herpes Labialis care, bringing new hope to patients worldwide.
DelveInsight's 'Herpes Labialis Pipeline Insight 2025' report provides comprehensive global coverage of pipeline Herpes Labialis therapies in various stages of clinical development. Major pharmaceutical companies are…
Microbiome Disease Clinical Pipeline | 140+ Companies Advancing Next-Generation …
The microbiome disease market is experiencing rapid growth and is driven by groundbreaking research and cutting-edge therapies. Industry leaders like MaaT Pharma, Qu Biologics, Biomica Ltd., and Seres Therapeutics are pioneering innovative treatment strategies, reshaping the landscape of microbiome-based therapeutics. As these transformative therapies progress through clinical development, they offer new hope for patients worldwide, redefining the future of microbiome disease management.
DelveInsight's 'Microbiome Disease Pipeline Insight 2025' report provides comprehensive…
Encephalopathy Clinical Pipeline | 70+ Companies Pioneering the Future of Treatm …
The encephalopathy market is advancing rapidly, driven by cutting-edge research and innovative therapies from leading companies such as Xenon Pharmaceuticals, Rebiotix, Axcella Health, Neurocrine Biosciences, and Takeda. These pioneers are transforming treatment approaches, reshaping the future of encephalopathy care, and providing new hope for patients worldwide.
DelveInsight's 'Encephalopathy Pipeline Insight 2025' report provides comprehensive global coverage of pipeline Encephalopathy therapies in various stages of clinical development. Major pharmaceutical companies are working…
More Releases for Metastatic
Metastatic Melanoma Cancer Diagnostics Market Analysis and Forecasts to 2031
Metastatic Melanoma Cancer Diagnostics Market 2022
The global Metastatic Melanoma Cancer Diagnostics Market is expected to grow on an impertinent note in the next 10 years. It could witness a CAGR of 8% and reach US$ 2.9 Bn by 2021 - 2031. Data processing through Big Data is on the anvil. Clinical software solutions are there to help out, taking the help of Big Data. Thus, data accumulation as well as…
Sacituzumab Govitecan Approval for Advanced or Metastatic Urothelial Cancer
On April 13, 2021, the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Sacituzumab Govitecan (from Gilead Sciences) for use in adult patients with locally advanced or metastatic urothelial cancer who have previously received platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or a programmed death-ligand 1 (PD-L1) inhibitor.
Sacituzumab govitecan is a first-in-class Trop-2-directed antibody-drug conjugated to a topoisomerase I inhibitor (SN-38). Trop-2 receptor, a protein frequently expressed in multiple types…
Global Metastatic Melanoma Treatment Market Growth 2020-2025
The recent COVID-19 report added by GLOBAL INFO RESEARCH gives a detailed account of the drivers and restraints in the global Metastatic Melanoma Treatment market. The research report, title[Global and China Metastatic Melanoma Treatment Market 2020 by Company, Type and Application, Forecast to 2025] presents a comprehensive take on the overall market. Analysts have carefully evaluated the milestones achieved by the global Metastatic Melanoma Treatment market and the current trends that are likely…
Metastatic Prostate Cancer Therapeutic and Disease Pipeline Review H2
Summary
“Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2017" provides an overview of Metastatic Prostate Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Metastatic Prostate Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end…
Metastatic Melanoma Market Growth with Worldwide Industry Analysis to 2024
A severe form of cancer, melanoma is commonly known as skin cancer. The population residing at higher altitude levels or in the close proximity to the equator, is the most susceptible to melanoma, as the symptoms are prominently initiated post-exposure to UV radiation that results in blistering sunburns. If diagnosed early in stage 0, melanoma can be surgically cured to almost 100%; however, when the disease metastizes in a body,…
Metastatic Hormone Refractory Prostate Cancer Market Lucrative Technological bre …
Cancer is one of the most fatal and chronic disorders, in which, there is development of tumor due to uncontrolled growth of cells in particular part of the body. Cancer is highly hazardous disease, in which, the mortality rate is extremely high, due to highly invasive nature and prolonged duration of disease.
Metastatic hormone refractory prostate cancer is the cancer of prostate glands. Prostate cancer is the most common form…
